These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11164719)

  • 1. Preclinical development of metalloproteasis inhibitors in cancer therapy.
    Giavazzi R; Taraboletti G
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):53-60. PubMed ID: 11164719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.
    Vihinen P; Kähäri VM
    Int J Cancer; 2002 May; 99(2):157-66. PubMed ID: 11979428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinase inhibitors: applications in oncology.
    Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
    Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review).
    Duffy MJ; McCarthy K
    Int J Oncol; 1998 Jun; 12(6):1343-8. PubMed ID: 9592197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.
    Jones L; Ghaneh P; Humphreys M; Neoptolemos JP
    Ann N Y Acad Sci; 1999 Jun; 880():288-307. PubMed ID: 10415874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibitors: present achievements and future prospects.
    Denis LJ; Verweij J
    Invest New Drugs; 1997; 15(3):175-85. PubMed ID: 9387040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases. Novel targets for directed cancer therapy.
    Yu AE; Hewitt RE; Connor EW; Stetler-Stevenson WG
    Drugs Aging; 1997 Sep; 11(3):229-44. PubMed ID: 9303281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases: multifunctional contributors to tumor progression.
    McCawley LJ; Matrisian LM
    Mol Med Today; 2000 Apr; 6(4):149-56. PubMed ID: 10740253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue inhibitors of matrix metalloproteinases in cancer.
    Blavier L; Henriet P; Imren S; Declerck YA
    Ann N Y Acad Sci; 1999 Jun; 878():108-19. PubMed ID: 10415723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies with matrix metalloproteinase inhibitors.
    Brown PD
    APMIS; 1999 Jan; 107(1):174-80. PubMed ID: 10190295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction.
    Khokha R; Waterhouse P
    J Neurooncol; 1994; 18(2):123-7. PubMed ID: 7525887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix metalloproteinase inhibitors as anticancer agents.
    Konstantinopoulos PA; Karamouzis MV; Papatsoris AG; Papavassiliou AG
    Int J Biochem Cell Biol; 2008; 40(6-7):1156-68. PubMed ID: 18164645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase inhibitors.
    Brown PD
    Breast Cancer Res Treat; 1998; 52(1-3):125-36. PubMed ID: 10066077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
    Rasmussen HS; McCann PP
    Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and clinical studies of MMP inhibitors in cancer.
    Drummond AH; Beckett P; Brown PD; Bone EA; Davidson AH; Galloway WA; Gearing AJ; Huxley P; Laber D; McCourt M; Whittaker M; Wood LM; Wright A
    Ann N Y Acad Sci; 1999 Jun; 878():228-35. PubMed ID: 10415734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects.
    Wong MS; Sidik SM; Mahmud R; Stanslas J
    Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
    Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.